SILVER SPRING
Tecentriq cleared for adjuvant bladder cancer with ctDNA guidance
- Sponsor
- Genentech $RHHBY
- Drug
- Tecentriq · atezolizumab
- Indication
- muscle-invasive bladder cancer
FDA approved Genentech's Tecentriq for adjuvant treatment of muscle-invasive bladder cancer using ctDNA-guided therapy.
What this means
Tecentriq is an immunotherapy drug that boosts the immune system by blocking a protein that helps cancer cells hide. The FDA approved Tecentriq for use after surgery in muscle-invasive bladder cancer patients whose tumors show signs of lingering cancer DNA in their blood. This decision could help doctors identify which patients may benefit most from the drug and potentially reduce the risk of cancer returning.
Drug Watch — recent news on Tecentriq
- Real-World Outcomes With Atezolizumab Plus Bevacizumab vs Durvalumab-Based Therapy - CancerNetwork
- Weighing Long-Term Survival and Quality of Life With Atezolizumab Plus Bevacizumab - CancerNetwork
- ES-SCLC: Consolidative thoracic RT with atezolizumab maintenance adds harm without survival gain - Vera Health
- Subcutaneous Atezolizumab Improves Day Hospital Nursing Workload, Chair Occupancy - Cancer Nursing Today
- Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer - OncLive
Sponsor Watch — recent news on Genentech
- Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
- Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption Accelerate
- Slate Medicines Appoints Mark W. Hahn to Board of Directors
- Roche Holding (SWX:ROP) Could Be 7% Undervalued On Pipeline Momentum
- Roche (SWX:ROG) Stock Could Trade At A Discount Despite Its 35% Run